Learn about Neurotorium and meet our editorial board

About Neurotorium

About Neurotorium

At Neurotorium.org, our mission is to improve awareness and knowledge of the brain and its diseases through online educational content created for clinicians, educators and all who are interested in learning more about the brain. We offer high-quality materials that are curated and reviewed by leading experts within the fields of psychiatry, neurology and neuroscience. Our content – images, PowerPoint slides, videos, etc. – is freely available for you to use, whether for self-study or to download and use in your own presentations. Neurotorium.org was founded by the Lundbeck Foundation, Lundbeckfonden.com

Meet our editorial board

David Nutt
David Nutt
Chair Editorial Board
chevron_right
Serge Gauthier
Serge Gauthier
Editorial Board
chevron_right
Lim Shen-Yang
Lim Shen-Yang
Editorial Board
chevron_right
John Kane
John Kane
Editorial Board
chevron_right
Philip Gorwood
Philip Gorwood
Editorial Board
chevron_right
#

Professor David Nutt

Edmond J Safra Professor of Neuropsychopharmacology in the Division of Brain Sciences Imperial College London.

David has held many leadership roles in psychiatry and neuroscience, including Presidencies of the European Brain Council, the European College of Neuropsychopharmacology (ECNP), the British Neuroscience Association and the British Association of Psychopharmacology. He was also Dean of Clinical Medicine at the University of Bristol and is currently the founding chair of Drug Science a charity that provides unbiased information about drugs and drug policy. He is a Fellow of the Royal Colleges of Physicians and Psychiatrists and has an honorary Doctor of Laws from the university of Bath.

His medical training was at Cambridge University and Guy’s Hospital London. After a spell in neurology to MRCP, he undertook psychiatric training in Guys and then Oxford continuing there as a lecturer and then later as a Wellcome Senior Fellow in psychiatry. He then spent two years as Chief of the Section of Clinical Science in the National Institute of Alcohol Abuse and Alcoholism in NIH, Bethesda, USA. On returning to England in 1988 he set up the Psychopharmacology Unit in Bristol University, an interdisciplinary research grouping spanning the departments of Psychiatry and Pharmacology before moving to Imperial College London in December 2008 where he leads a similar group with a particular focus on brain imaging especially PET

He edited the Journal of Psychopharmacology for 28 years is a psychiatry drugs advisor to the British National Formulary. He has published over 500 original research papers, a similar number of reviews and book chapters, eight government reports on drugs and 36 books.

He broadcasts widely to the general public both on radio and television including BBC science and public affairs programmes on therapeutic as well as illicit drugs, their harms and their classification. He also lecturers widely to the public as well as to the scientific and medical communities. In 2010 The Times Eureka science magazine included him in the 100 most important figures in British Science, and the only psychiatrist and in 2013 he was awarded the John Maddox Prize from Nature/Sense about Science for promoting evidence in the face of political pressure.

#

Professeur Serge Gauthier

McGill University Research Centre for Studies in Aging, Montréal, Québec, Canada.

His special interests include consensus approach to the management of Alzheimer’s disease across its different stages, the ethics of research involving persons with dementia, and prevention strategies against cognitive decline associated with aging.

Serge Gauthier, CM, CQ, MD (retired) completed his medical studies at the Université de Montréal, Neurology training at McGill University, and a Research Fellowship in Professor TL Sourkes’ laboratory, Allen Memorial Institute, Montreal. He was clinical investigator and staff neurologist at the Montreal Neurological Hospital and Institute (1976–1986), Director of the McGill Centre for Studies in Aging (1886–1996), and Senior Scientist of the Canadian Institutes of Health Research and Canada’s Research-Based Pharmaceutical Companies (CIHR-Rx&D) program (1997–2007). Serge Gauthier is currently Emeritus Professor of Neurology and Psychiatry at McGill University. He was a recipient of the Order of Canada in 2014 and the Ordre national du Québec in 2018.

Serge Gauthier’s contributions to research include design and implementation of randomized clinical trials in order to establish the safety and efficacy of cholinesterase inhibitors, memantine, and agents possibly modifying the progression of Alzheimer’s disease. He has published over 700 peer reviewed articles and 35 books, and is currently leading the McGill team writing the World Alzheimer Report 2022 on Post-Diagnostic Support for Dementia.

#

Professor, MBBS MD FRACP FASc Lim Shen-Yang

Neurologist and Professor at the University of Malaya, Kuala Lumpur, Malaysia

Dr. Lim is a Neurologist and Professor at the University of Malaya, Kuala Lumpur, Malaysia, where he runs a busy clinical practice specializing in Parkinson’s and related disorders. Dr. Lim has published extensively in these areas, in major scientific journals such as Lancet Neurology, Annals of Neurology, Neurology, JAMA Neurology, Movement Disorders, Nature Genetics, etc.

He has been an active member of the International Parkinson & Movement Disorder Society (MDS), being closely involved in multiple Committees (previously Chair of the MDS Asian-Oceanian Section [AOS] Education Committee; and currently Chair-Elect of the MDS-AOS) and Task Forces (for Evidence-Based Medicine, Palliative Care, Movement Disorders in Asia; PD Diagnostic Criteria, etc.).

With a strong commitment to teaching/training, Dr. Lim has organized numerous teaching courses on Parkinson’s & movement disorders, and delivered and/or participated in >200 international-level lectures and expert panels (in the United States, Canada, United Kingdom, Germany, France, Australia, Japan, Singapore, China, India, South Korea, Hong Kong, Taiwan, Thailand, Indonesia, Philippines, Sri Lanka, Brunei, Myanmar, United Arab Emirates, Kyrgyzstan, Mongolia, etc.). These have included Plenary Lectures at MDS Congresses (Toronto 2011, Dublin 2012, Nice 2019, Philadelphia/Virtual 2020) and at the World Parkinson’s Congress (Kyoto 2019).

#

Professor John Kane

Professor of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, New York.

John M. Kane, MD, is Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and Director of the Institute of Behavioural Science at the Feinstein Institutes for Medical Research. Dr. Kane earned his medical degree from New York University in New York, New York, and completed his internship and residency in Psychiatry at The Zucker Hillside Hospital. He is a Diplomate of the American Board of Psychiatry and Neurology.

Dr. Kane is the recipient of many awards, including the Lieber Prize, The APA’s Kempf Award and Foundations Prize, the New York State Office of Mental Health Lifetime Achievement Award, The Dean Award from the American College of Psychiatrists. He has served as President of the American Society of Clinical Psychopharmacology, the Psychiatry Research Society and the Schizophrenia International Research Society. Dr. Kane has been the principal investigator for research projects focusing on schizophrenia, psychobiolgy and treatment, recovery, and improving quality and cost of care. He is the author of over 800 peer-reviewed papers and serves on the editorial boards of numerous journals.

#

Professeur Philip Gorwood

Prof Philip Gorwood, MD, PhD. Head of CMME, Hospital Sainte-Anne (Paris University) and head of team 1 (INSERM U1266), Institute of Psychiatry and Neurosciences of Paris (IPNP).

Professor Gorwood has published over 300 scientific articles and 24 book chapters. Professor Gorwood studied medicine from 1982-1988 and specialised in psychiatry in 1988. He is currently full Professor of Psychiatry at Sainte-Anne Hospital (CMME department, with 60 beds), teaching at the University of Paris. He is Head of the Team 1 of the 1266 unit (Institute of Psychiatry and Neurosciences of Paris), of the French lnstitute of Medical Research (INSERM) devoted to the genetic vulnerability of psychiatric and addictive disorders. 

Professor Gorwood has published over 300 scientific articles (h-index=45) and 24 book chapters. He has served on 16 editorial boards for journals in psychiatry, neuroscience, and genetics, and was for 12 years editor-in-chief of the journal European Psychiatry (IF=5.1). He is now the immediate past-president, member of the Core Organising and Scientific Committee (COSC), Executive Committee (EC) and board member of the European Psychiatric Association (EPA). He joined the scientific advisory (SAB) board of the ECNP for addictive disorders in 2009.

task_alt